1. Home
  2. BTQ vs IMMP Comparison

BTQ vs IMMP Comparison

Compare BTQ & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BTQ

BTQ Technologies Corp.

N/A

Current Price

$3.54

Market Cap

448.1M

Sector

N/A

ML Signal

N/A

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.55

Market Cap

58.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTQ
IMMP
Founded
1983
1987
Country
Canada
Australia
Employees
27
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
448.1M
58.2M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
BTQ
IMMP
Price
$3.54
$0.55
Analyst Decision
Strong Buy
Hold
Analyst Count
1
3
Target Price
$10.00
$5.50
AVG Volume (30 Days)
2.0M
867.5K
Earning Date
03-31-2026
04-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$2,332.99
$417.85
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.09
$0.29
52 Week High
$16.00
$3.53

Technical Indicators

Market Signals
Indicator
BTQ
IMMP
Relative Strength Index (RSI) 67.02 36.54
Support Level $2.23 N/A
Resistance Level $3.83 $1.75
Average True Range (ATR) 0.25 0.06
MACD 0.13 0.10
Stochastic Oscillator 98.74 36.05

Price Performance

Historical Comparison
BTQ
IMMP

About BTQ BTQ Technologies Corp.

BTQ Technologies Corp is engaged in the development of computer-based technology related to post-quantum cryptography, particularly as it applies to blockchain and related technologies, and their protection from the emerging security risk of quantum computing. Its products include PQScale, Keelung, Kenting, and Qbyte. PQScale is a novel scaling technique for post-quantum cryptographic primitives. Keelung is a zero-knowledge toolkit for fast, private, and secure applications. Kenting provides acceleration for NIST-compliant post-quantum cryptography, post-quantum zk-SNARKs, and eco-friendly mining hardware, and Qbyte is a quantum risk calculator. Geographically, the company derives maximum revenue from Canada, and also has a presence in Taiwan, and Australia.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: